MedTrace Logo

RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT

NCT05858814 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-05-19

No results posted yet for this study

Summary

To evaluate the safety and tolerability of RC1012 injection infusion in AML Patients after Allo-HSCT

Conditions

Interventions

BIOLOGICAL

RC1012 injection (allo-DNT cells)

RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • Guangdong Ruishun Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Xiaoyu Zhu, MD, PhD · Anhui Provincial Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-04
Primary Completion
2024-05-27
Completion
2026-06-24

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05858814 on ClinicalTrials.gov